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BACKGROUND: A better understanding of the factors that contribute 
to heterogeneous outcomes and lifetime disease burden in hypertrophic 
cardiomyopathy (HCM) is critically needed to improve patient management 
and outcomes. The SHaRe registry (Sarcomeric Human Cardiomyopathy 
Registry) was established to provide the scale of data required to address 
these issues, aggregating longitudinal data sets curated by 8 international 
HCM specialty centers.
METHODS: Data on 4591 patients with HCM (2763 genotyped) followed 
up for a mean of 5.4±6.9 years (24 791 patient-years; median, 2.9 years; 
interquartile range, 0.3–7.9 years) were analyzed for cardiac arrest, cardiac 
transplantation, appropriate implantable cardioverter-defibrillator therapy, all-
cause death, atrial fibrillation, stroke, New York Heart Association functional 
class III/IV symptoms (all making up the overall composite end point), and left 
ventricular ejection fraction <35%. Outcomes were analyzed individually and 
as composite end points.
RESULTS: Median age at diagnosis was 45.8 (interquartile range, 30.9–58.1) 
years, and 37% of patients were female. Age at diagnosis and sarcomere 
mutation status were predictive of outcomes. Patients <40 years old at diagnosis 
had a 77% (95% CI, 72–80) cumulative incidence of the overall composite 
outcome by 60 years of age compared with 32% (95% CI, 29–36) by 70 years 
of age for patients diagnosed at >60 years old. Young patients with HCM (age, 
20–29 years) had 4-fold higher mortality than the general US population at a 
similar age. Patients with pathogenic/likely pathogenic sarcomere mutations 
had a 2-fold greater risk for adverse outcomes compared with patients without 
mutations; sarcomere variants of uncertain significance were associated with 
intermediate risk. Heart failure and atrial fibrillation were the most prevalent 
adverse events, although typically not emerging for several years after diagnosis. 
Ventricular arrhythmias occurred in 32% (95% CI, 23–40) of patients <40 years 
of age at diagnosis but in 1% (95% CI, 1–2) of those >60 years old at diagnosis.
CONCLUSIONS: The cumulative burden of HCM is substantial and 
dominated by heart failure and atrial fibrillation occurring many years after 
diagnosis. Young age at diagnosis and the presence of a sarcomere mutation 
are powerful predictors of adverse outcomes. These findings highlight the 
need for close surveillance throughout life and the need to develop disease-
modifying therapies.
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Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular (LV) hypertrophy that occurs in the absence of 
identifiable processes that could account for such re-
modeling. HCM has been the focus of intense clinical 
and basic science investigation for decades. These ef-
forts have provided remarkable insights into both the 
molecular basis and clinical course of disease, defining 
sarcomere mutations as the most common genetic ba-
sis of HCM1 and improving understanding from the ear-
ly perception of a highly mortal condition.2–4 Although 
disease course is variable, many patients experience 
adverse clinical outcomes, including heart failure (HF), 
arrhythmias, and sudden cardiac death. Marked clinical 
heterogeneity and limited longitudinal data, particularly 
on large genotyped cohorts, have been major barriers 
to gaining an accurate and comprehensive description 
of the natural history of HCM. Determining the rela-
tionship among genotype, phenotype, and outcomes 
over a lifetime is critical to improve risk stratification 
and to guide patient management. Such insights are 
also needed to support the development of targeted 
therapies intended to modify disease progression and 
to prevent adverse sequelae.
The SHaRe registry (Sarcomeric Human Cardiomy-
opathy Registry) is an international database of patients 
with primary cardiomyopathies. Detailed data sets 
from expert centers were centralized and harmonized 
to create a large, comprehensive, collaborative registry 
of patients with HCM. The scale of these data, span-
ning >24 000 patient-years, provides the opportunity to 
quantify cumulative disease burden in HCM, to define 
present-day risk estimates, and to determine how sar-
comere mutations influence disease.
METHODS
Participating Sites and Creation of the 
Centralized Database
SHaRe was established by 8 experienced, high-volume HCM 
centers (Figure IA in the online-only Data Supplement) that 
maintain longitudinal databases capturing clinical, genetic, 
and outcomes data on patients with HCM and families under 
care. Definitions were harmonized for key demographic, his-
torical, clinical, and genetic parameters. Particular attention 
was paid to gain complete ascertainment of historical events 
that occurred before SHaRe entry. This was accomplished 
through systematic and thorough review of medical history 
and medical records, both at the initial visit and at subsequent 
visits. Site data (without protected health information) were 
mapped to 762 discrete corresponding fields in the secure cen-
tralized database to yield standardized SHaRe definitions and 
values (Boston Advanced Analytics, Boston, MA). Prospective 
data were captured via quarterly uploads from site databases. 
Institutional review board and ethics approval was obtained in 
accordance with policies applicable to each SHaRe site.
The data will not be made available to other research-
ers for purposes of reproducing the results or replicating the 
procedure because of constraints related to human subjects 
research. Analytical methods will be made available on request.
Study Population, Genetic Testing, and 
Variant Classification
Inclusion criteria included a site-designated diagnosis of HCM, 
defined as unexplained LV hypertrophy with maximal LV wall 
thickness >13 mm (or equivalent z score for pediatric patients), 
integrating extracardiac features, familial context or sporadic 
occurrence, and genotype to allow an informed diagnosis by 
experienced clinicians. Inclusion also required ≥1 clinic visit 
at a SHaRe site since 1960 and ≥1 echocardiographic assess-
ment of LV wall thickness (Figure IB in the online-only Data 
Supplement). All analyzed metrics of cardiac dimensions 
and function were based on echocardiographic measure-
ments. Genetic testing was performed at all sites using dif-
ferent platforms available over time. Variants were classified 
as pathogenic, likely pathogenic, unknown significance, or 
Clinical Perspective
What Is New?
• This study analyzed longitudinal clinical informa-
tion on 4591 patients with hypertrophic cardiomy-
opathy (HCM) who receive care at 8 high-volume 
multinational HCM specialty centers.
• In an examination of a data set spanning >24 000 
patient-years, the mortality of patients with HCM 
was shown to be ≈3-fold higher than that of the 
US general population at similar ages.
• The lifetime cumulative morbidity of HCM was 
considerable, particularly for patients diagnosed 
before 40 years of age and patients with sarcomere 
mutations.
• Atrial fibrillation and heart failure were the domi-
nant components of disease burden.
• This work highlights the power of international 
collaboration to study complex and heterogeneous 
disease.
What Are the Clinical Implications?
• Younger age at diagnosis and the presence of a 
sarcomere mutation were strong predictors of 
adverse events.
• Considering these factors will likely improve prog-
nostication and risk stratification for individual 
patients with HCM.
• Although the incidence of ventricular arrhythmias 
declined with age, the risk for heart failure and 
atrial fibrillation increased, becoming most preva-
lent by mid- to late adulthood, even in patients 
diagnosed before 40 years of age.
• These observations underscore the need for lifelong 
surveillance and for developing effective strategies 
to prevent the progressive and adverse remodeling 
that leads to these complications.
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likely benign/benign by each site using contemporary crite-
ria,5 focusing on the 8 sarcomere genes definitively associated 
with HCM (myosin binding protein C [MYBPC3], myosin heavy 
chain [MYH7], cardiac troponin T [TNNT2], cardiac troponin I 
[TNNI3], α-tropomyosin [TPM1], myosin essential and regula-
tory light chains [MLY2, MYL3], and actin [ACTC]). Sarcomere 
variants in the SHaRe database underwent additional system-
atic review by a subgroup of investigators (A.L.C., S.M.D., 
J.S.W., C.Y.H.; Methods in the online-only Data Supplement) 
to adjudicate and standardize classification. Genotyped 
patients were then designated as SARC+ (at least 1 patho-
genic or likely pathogenic variant in any of the above sar-
comere genes), which includes the subsets SARC1+ (only 1 
pathogenic or likely pathogenic mutation) and SARC2+ (>1 
pathogenic or likely pathogenic sarcomere mutation); SARC 
VUS (sarcomere variant of unknown significance present); and 
SARC− (no potentially pathogenic variants identified in a sar-
comere gene). Patients were excluded if they had potentially 
pathogenic variants in genes encoding nonsarcomere proteins 
such as α-galactosidase (GLA) or lysosome-associated mem-
brane protein (LAMP2) indicating the presence of metabolic 
or storage disease or other diagnoses. Table I in the online-
only Data Supplement includes all gene variants identified in 
SHaRe, their classification, and their frequency in SHaRe.
Outcome Definitions
Composite outcomes were defined to organize events into 
clinically relevant and related groups and to maximize statisti-
cal power. Outcomes were documented by the primary car-
diologist at each site during clinical encounters and captured 
directly into the database:
• Ventricular arrhythmic composite: first occurrence of sud-
den cardiac death, resuscitated cardiac arrest, or appro-
priate implantable cardioverter-defibrillator therapy
• HF composite: first occurrence of cardiac transplantation, 
LV assist device implantation, LV ejection fraction <35%, 
or New York Heart Association class III/IV symptoms
• Overall composite: first occurrence of any component 
of the ventricular arrhythmic or heart failure composite 
end point (without inclusion of LV ejection fraction), all-
cause mortality, atrial fibrillation (AF), stroke, or death
Statistical Analysis
Retrospective data were analyzed from the ongoing prospec-
tive registry study. Natural history was described in terms of 
age at first occurrence of each composite outcome and indi-
vidual components with Kaplan-Meier analyses. Patients who 
did not have the outcome of interest were censored at the 
time of their last recorded follow-up in SHaRe. Patients missing 
data on the occurrence or timing of events were not included 
in analyses of those outcomes. However, to maximize sample 
sizes across analyses, such patients were included in analyses 
of other outcomes for which data were available.
Analyses were first performed in the full HCM cohort, made 
up of all eligible SHaRe patients. To characterize lifetime mor-
bidity, cumulative incidence from birth of AF and the 3 com-
posite outcomes was derived from the Kaplan-Meier analyses 
of these outcomes. These analyses were stratified by age at 
diagnosis (<40, 40–60, >60 years). In addition, the occurrence 
of incident events after HCM diagnosis was analyzed, and 
annualized postdiagnosis incidence rates of the overall com-
posite were calculated for each age at diagnosis stratum. To 
contextualize mortality rates observed in patients with HCM, 
age-specific mortality rates from SHaRe sites in the United 
States derived from the Kaplan-Meier analyses were compared 
with mortality rates in the US general population from 1999 
to 2014 obtained from the Centers for Disease Control and 
Prevention Wonder database (http://wonder.cdc.gov/).
Analyses were then performed in the genotyped HCM 
cohort, made up of patients who underwent genetic testing 
to determine sarcomere mutation status. Ages at first event 
were compared for patients stratified by sarcomere genotype 
using hazard ratios based on Cox proportional hazards mod-
els with family-specific frailty effects to account for correla-
tion resulting from relatedness. Selected outcomes were also 
analyzed in multivariable models. Mortality was compared 
between patients with nonfamilial HCM (sarcomere-negative 
patients without a family history of HCM) and familial HCM 
(SARC+, SARC VUS, or family history of HCM). Age-specific 
mortality in the subset of patients with nonfamilial HCM was 
also compared with the US general population mortality as 
done for the full HCM cohort. Additional details are provided 
in Methods in the online-only Data Supplement.
RESULTS
Clinical Characteristics
Among patients with HCM receiving care at a SHaRe 
site between 1960 and December 2016 (n=5669), 4591 
met inclusion criteria and make up the full HCM cohort 
(Figure IB in the online-only Data Supplement). Baseline 
characteristics and descriptive information on outcomes 
are summarized in Table 1. Most individuals were pro-
bands (first family member presenting for care at the 
site); affected relatives made up 12% of the cohort 
(552 of 4591). Median (interquartile range [IQR]) time 
of follow-up from the time of first encounter at a SHaRe 
site was 2.9 (IQR, 0.3–7.9) years, representing a total of 
24 791 patient-years. Median age at diagnosis was 45.8 
(IQR, 30.9–58.1) years, and 37% (1704 of 4591) were 
female. Forty-one percent of patients (n=1834 of 4591) 
reached the overall composite outcome. Events were 
most frequently AF (20% of patients) and HF (22% of 
patients), whereas 6% of patients (n=270) met the ven-
tricular arrhythmia composite.
A total of 2763 patients (60%) had genetic testing. Fig-
ure II in the online-only Data Supplement shows summary 
results of genetic testing in the 2405 probands tested. 
A pathogenic/likely pathogenic sarcomere variant was 
identified in 46% of all patients tested (SARC+, n=1279), 
including 34 subjects who carried ≥2 pathogenic/likely 
pathogenic variants (SARC2+); 9% had a variant of un-
known significance (SARC VUS, n=253). Forty-five percent 
had negative genetic testing results (SARC−, n=1231). 
The median age at diagnosis was 13.6 years younger in 
SARC+ compared with SARC− patients (37.5 [IQR, 23.6–
49.8] years versus 51.1 [IQR, 38.3–61.8] years; P<0.001).
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Natural History of HCM: Mortality and 
Cumulative Burden of Disease
During follow-up, 370 patients (8%) died, including 
58 sudden deaths (16% of deaths; 1% of the cohort). 
In addition, 120 patients had resuscitated cardiac ar-
rest (3% of the cohort). Lifetime morbidity from HCM 
was analyzed by examining the cumulative incidence 
of events from birth to age 70 years in each age at 
diagnosis stratum separately (Figure 1A–1D). Younger 
age at diagnosis was associated with an increased cu-
Table 1. Baseline Characteristics and Events
Full HCM Cohort 
(n=4591)
Genotyped HCM Subset (n=2763)
P Values for Differences Between 
Sarcomere Groups
SARC− (n=1231, 
44.6%)
SARC+ (n=1279, 
46.3%)
SARC VUS 
(n=253, 9.1%) Overall
SARC+ vs 
SARC−
SARC VUS 
vs SARC−
Baseline characteristics
  Female, n (%) 1704 (37) 419 (34) 504 (39) 85 (34) <0.05 <0.01 0.95
  Age at diagnosis, median (IQR), y 45.8 (30.9–58.1) 51.1 (38.3–61.8) 37.5 (23.6–49.8) 44.0 (31.4–54.1) <0.001 <0.001 <0.001
   Mean±SD 44.3±18.5 49.0±17.4 37.3±17.1 41.9±17.9    
  Follow-up time, median (IQR), y 2.9 (0.3–7.9) 3.2 (0.4–7.5) 5.4 (1.5–10.6) 2.7 (0.3–7.0) <0.001 <0.001 0.70
   Mean±SD 5.4±6.9 5.0±6.1 7.8±8.4 5.2±6.7    
  Race, n (%)     <0.001 <0.01 <0.05
   White 3911 (85) 1074 (87) 1156 (90) 205 (81)    
   Black 141 (3) 42 (3) 22 (2) 9 (4)    
   Other/not reported 539 (12) 115 (9) 101 (8) 39 (15)    
  Family history HCM, n (%) 1628 (35) 302 (25) 741 (58) 101 (40) <0.001 <0.001 <0.001
  Family proband, n (%) 4039 (88) 1177 (96) 997 (78) 229 (91) <0.001 <0.001 <0.01
  NYHA class III/IV, n (%) 597 (13) 167 (14) 134 (10) 33 (13) 0.11 <0.05 0.98
  Maximal LVWT, median (IQR), mm 18 (15–22) 17 (15–21) 19 (15–23) 18 (15–23) <0.001 <0.001 <0.001
   Mean±SD 18.7±5.8 18.1±5.2 19.7±6.2 19.4±6.3    
  LVEF, median (IQR), % 65 (60–71) 65 (60–72) 65 (60–70) 65 (60–73) <0.01 <0.01 0.85
   Mean±SD 65.0±9.6 65.6±9.4 64.3±9.5 65.8±9.6    
  Peak gradient category, n (%)
   >30 mm Hg 1291 (28) 462 (38) 263 (21) 78 (31) <0.001 <0.001 0.05
   <30 mm Hg 3300 (72) 769 (62) 1016 (79) 175 (69)    
Patients with events, n (%)
  All-cause death 370 (8) 80 (7) 97 (8) 17 (7)    
  Sudden death 58 (1) 13 (1) 22 (2) 3 (1)    
  Resuscitated cardiac arrest 120 (3) 34 (3) 40 (3) 7 (3)    
  ICD present 961 (21) 224 (18) 383 (30) 68 (27)    
  Appropriate ICD therapy 
(including antitachycardia pacing)
135 (3) 30 (2) 64 (5) 10 (4)    
  Appropriate ICD shock (excluding 
antitachycardia pacing)
113 (3) 22 (2) 55 (4) 9 (4)    
  AF 920 (20) 254 (21) 295 (23) 58 (23)    
  Stroke 201 (4) 54 (4) 53 (4) 13 (5)    
  Transplantation or LVAD 74 (2) 10 (1) 34 (3) 1 (0)    
  Overall composite 1834 (41) 515 (43) 532 (42) 101 (42)    
  Ventricular arrhythmia composite 270 (6) 67 (5) 108 (8) 17 (7)    
  HF composite 996 (22) 277 (23) 290 (23) 52 (21)    
Echocardiographic characteristics were summarized at the patient’s first echocardiography visit in the SHaRe registry (Sarcomeric Human Cardiomyopathy Registry). 
NYHA class was summarized at the patient’s first clinic visit in SHaRe. The percentage of patients with missing data on key variables in each cohort is as follows: for 
LVEF: full HCM cohort, 18%; SARC−, 11%; SARC+, 23%; and SARC VUS, 20%; for NYHA class: full HCM cohort, 13%; SARC−, 7%; SARC+, 10%; and SARC VUS, 
9%. AF indicates atrial fibrillation; HCM, hypertrophic cardiomyopathy; HF, heart failure; ICD, implantable cardioverter-defibrillator; IQR, interquartile range; LVAD, 
left ventricular assist device; LVEF, left ventricular ejection fraction; LVWT, left ventricular wall thickness; NYHA, New York Heart Association; SARC, sarcomere; and 
VUS, variants of uncertain significance.
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mulative incidence of events throughout life, although 
events largely occurred in later decades. Patients <40 
years old at diagnosis had a 77% (95% CI, 72–80) 
cumulative incidence of the overall composite out-
come by age 60 years (Figure 1A). In contrast, patients 
>60 years of age at diagnosis had a 32% (95% CI, 
29–36) cumulative incidence of the overall composite 
outcome by 70 years of age. For all age at diagnosis 
strata, outcomes were dominated by HF (Figure  1C) 
and AF (Figure 1D), occurring most frequently between 
50 and 70 years of age. More than 80% of patients 
who developed New York Heart Association class III/
IV symptoms had LV ejection fraction >55% (data not 
shown). Lifetime cumulative incidence of malignant 
ventricular arrhythmias was 32% (95% CI, 23–40) in 
patients diagnosed at <40 years of age but was rarely 
encountered (1%; 95% CI, 1–2) in the oldest age at 
diagnosis stratum (Figure 1B). Results were comparable 
when analyses were repeated including only probands 
(data not shown), suggesting limited bias associated 
with ascertaining family members.
Analyses characterizing incident events occurring af-
ter the time of diagnosis demonstrated that patients 
diagnosed at older ages had a higher annualized risk of 
incident occurrence of the overall composite outcome 
(Table II in the online-only Data Supplement). This in-
creased postdiagnosis risk is consistent with the steeper 
slope of the cumulative incidence plot for the older 
diagnosed patients compared with the younger diag-
nosed patients (Figure 1A).
Compared with the US general population, mortality 
was >4-fold higher for young patients with HCM at US 
Figure 1. Age at diagnosis is associated with the lifetime cumulative burden of events.  
These curves depict the cumulative incidence of events from birth for outcomes of interest, stratified by age at diagnosis <40, 40 to 60, and >60 years. Earlier 
age at diagnosis is associated with a higher burden of adverse events. Shaded areas indicate 95% CIs. A, Overall composite outcome. B, Ventricular arrhythmia 
composite. C, Heart failure composite. D, Atrial fibrillation.
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sites (age, 20–29 years; 0.39% versus 0.09%; P<0.05) 
and ≥3-fold higher in patients with HCM who were 50 
to 69 years of age (P<0.01; Figure 2A). These findings 
of excess mortality remained comparable when patients 
with HCM cared for at non-US sites were included in 
analyses (data not shown).
Sarcomere Mutations Are Associated 
With Earlier Onset and Higher Incidence 
of Events
Survival analyses demonstrated that both SARC+ and 
SARC VUS patients had significantly earlier onset of 
events and a higher incidence of the overall composite 
outcome, HF, and AF than SARC− patients (Figure 3A, 
3C, and 3D). SARC+ patients had significantly higher 
risk for the ventricular arrhythmia composite compared 
with SARC− patients, but no significant difference was 
seen between the SARC VUS and SARC− cohorts (Fig-
ure 3B). No significant difference was identified when 
each of the composite outcomes and AF were com-
pared in the SARC+ and SARC VUS cohorts. Cox analy-
ses demonstrated a higher incidence of adverse events 
in SARC+ versus SARC− patients across all composite 
and individual outcomes (Figure  4A). SARC+ patients 
had at least twice the lifetime hazard of death, HF, ma-
lignant arrhythmias, and AF compared with SARC− pa-
tients; risk for cardiac transplantation/LV assist device 
support was >4 times higher (hazard ratio [HR], 4.6; 
95% CI, 2.3–9.4). Similarly, SARC VUS patients had a 
significantly higher incidence of the overall compos-
ite (HR, 1.5; 95% CI, 1.2–1.9), death (HR, 1.9; 95% 
CI, 1.1–3.4), and AF (HR, 1.8; 95% CI, 1.3–2.5) com-
pared with SARC− patients (Figure 4B). In contrast, HRs 
were similar between SARC+ and SARC VUS patients, 
although SARC+ patients had a nearly 6-fold increase 
in risk for LV ejection fraction <35% (Figure 4C). Pa-
tients with >1 mutation (SARC2+) had the highest risk 
for transplantation/LV assist device (HR, 7.5; 95% CI, 
2.7–20.5 compared with patients with 1 mutation) and 
stroke (HR, 5.1; 95% CI, 2.0–12.6; Figure III in the on-
line-only Data Supplement). In a comparison of patients 
with mutations in MYH7 and MYBPC3, MYH7 muta-
tion carriers had a ≈1.7- to nearly 3-fold higher risk of 
the overall composite outcome, AF, and advanced HF 
(New York Heart Association functional class III/IV and/
or need for cardiac transplantation or LV assist device; 
Figure IV in the online-only Data Supplement).
Figure 2. Age-specific mortality in hypertrophic cardiomyopathy (HCM) compared with the general US population from 1999 to 2014. 
Data from US SHaRe registry (Sarcomeric Human Cardiomyopathy Registry) sites were compared with the Centers for Disease Control and Prevention Wonder 
database (http://wonder.cdc.gov/) to estimate US general population mortality rates from 1999 to 2014. A, Compared with the general US population, patients 
with HCM have significantly increased mortality in the youngest and older age groups. B, When the comparison was restricted to the nonfamilial HCM cohort (no 
sarcomere mutation and no family history of HCM), overall mortality appears similar to that of the general US population. Error bars represent 95% CIs.
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Predictors of Clinical Outcomes in the 
Genotyped HCM Cohort
Multivariable models were developed to identify pa-
tient characteristics associated with the composite 
outcomes and AF (Table 2). After controlling for pro-
band status, sex, and race, the presence of a sarco-
mere mutation carried a >2-fold increased risk for all 
outcomes, highest for ventricular arrhythmias (HR, 2.8; 
95% CI, 2.1–3.9; P<0.001). Because sarcomere status 
is correlated to age at diagnosis, models were also run 
including age at diagnosis as a covariate. The hazard 
for SARC+ was attenuated but remained significantly 
elevated after adjustment for age at diagnosis (data not 
shown), supporting that the increased hazard associat-
ed with carrying a sarcomere mutation is not mediated 
entirely by earlier age at diagnosis. Woman had an al-
most 30% lower risk for AF and malignant arrhythmias 
but a similarly higher risk for HF. Patients with multiple 
pathogenic or likely pathogenic sarcomere mutations 
had >2-fold increased risk for the overall composite and 
>4-fold increased risk for ventricular arrhythmias rela-
tive to patients without sarcomere mutations (Table III 
in the online-only Data Supplement).
Figure 3. Association between sarcomere mutations and clinical outcomes. 
Kaplan-Meier survival analyses were performed in the genotyped hypertrophic cardiomyopathy (HCM) subset. Compared with patients with HCM without sar-
comere mutations (SARC−), sarcomere mutation carriers (SARC+) have earlier and a higher incidence of adverse outcomes, particularly those with pathogenic 
and likely pathogenic variants. A, The risk of developing the overall composite outcome by age 50 years is 29.1% for SARC+ patients vs 24.9% for carriers 
of a variant of unknown significance (SARC VUS) and 14.2% for SARC− patients. B, Ventricular arrhythmia composite outcome. C, Heart failure composite 
outcome. D, Atrial fibrillation.
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Patients with nonfamilial HCM (SARC− and no family 
history of HCM) had a lower risk of mortality and composite 
outcomes than other patients with HCM (HR 0.57 [0.49, 
0.65] for the overall composite outcome and 0.46 [0.33, 
0.64] for death). In addition, their age-specific mortality was 
similar to that of the US general population (Figure 2B).
DISCUSSION
SHaRe represents the largest comprehensive HCM co-
hort assembled to date, thereby providing critical new 
insights into natural history and lifetime risk of disease 
complications. In an examination of >24 000 patient-
Figure 4. Forest plots showing hazard ratios (HRs) for the composite end points and their individual components, comparing sarcomere mutation 
carriers (SARC+), patients with hypertrophic cardiomyopathy (HCM) without sarcomere mutations (SARC−), and carriers of a variant of unknown 
significance (SARC VUS) cohorts.  
A, SARC+ vs SARC−: Sarcomere mutation carriers have a higher risk of all individual components of the composite end points compared with patients with HCM 
without sarcomere mutations. B, SARC VUS vs SARC−: SARC VUS patients have a higher risk of the overall composite end point, death, appropriate implantable 
cardioverter-defibrillator (ICD) firing, atrial fibrillation, and heart failure (HF) with ejection fraction (EF) >55%. C, SARC+ vs SARC VUS: SARC+ and SARC VUS pa-
tients have similar risks except for a markedly higher hazard for left ventricular (LV) EF <35% and need for cardiac transplantation or ventricular assist device (VAD) 
in SARC+ patients. NYHA indicates New York Heart Association.
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years of experience with disease, the cumulative burden 
of HCM was shown to be substantial, particularly for 
patients diagnosed earlier in life and those with sarco-
mere mutations. Although the incidence of ventricular 
arrhythmias declined with age, the risk for HF and AF 
increased, becoming most prevalent by late adulthood, 
even in patients diagnosed before 40 years of age. 
These observations underscore the need for lifelong 
surveillance and for developing effective strategies to 
prevent the progressive and adverse cardiac remodeling 
that leads to these complications.
Morbidity and Mortality in HCM
Published HCM natural history studies reflect a medi-
an of ≈3700 patient-years of follow-up and have not 
considered cumulative risks of morbidity and mortality, 
nor have they systematically included genetic back-
ground.2,6–11 In contrast, we leveraged longitudinal 
data from a large international cohort to provide more 
precise and widely representative characterization of 
event rates and disease burden throughout life. Data 
from SHaRe demonstrate that mortality in patients 
with HCM is significantly higher than in the US gen-
eral population. Although SHaRe data confirmed that 
absolute mortality in young patients with HCM is low, 
it was 4-fold higher than expected for 20- to 29-year-
olds. In addition, although prior natural history studies 
(combined n=1700) reported sudden cardiac death as 
the leading cause of mortality in HCM, accounting for 
≈40% of deaths,2,6 our data (n=4591) indicated that 
16% of deaths were sudden. Overall mortality in SHaRe 
was driven by HF and noncardiac death, both of which 
were more common than lethal arrhythmias, consistent 
with recent evidence from other cohorts.4 Nonethe-
less, among patients diagnosed at a young age (<40 
years), the cumulative incidence of lethal arrhythmias 
was 26% by 60 years of age, underscoring the need 
to incorporate age-specific risk predictions into clinical 
decision-making for primary prevention implantable 
cardioverter-defibrillator therapy. Further studies are 
needed to determine whether incorporating age at di-
agnosis, in addition to current age, improves sudden 
cardiac death risk assessment and predictive scores.12
Cumulative morbidity in HCM was dominated by 
complications related to HF and AF. Among patients 
diagnosed before 40 years of age, the risk of having 
HF or AF by age 60 years was 47% (95% CI, 42–52) 
and 62% (95% CI, 56–67), respectively. For context, a 
40-year-old in the US general population has a lifetime 
risk of 20% to 45% for HF and 23% to 26% (women 
and men, respectively) for AF.13 SHaRe also demonstrat-
ed that regardless of age at diagnosis, the majority of 
HCM-related complications occurred later in life, peak-
ing between 50 and 70 years of age. Therefore, con-
tinuing clinical surveillance in older patients with HCM 
is critical. Although ventricular arrhythmias and sudden 
death were indeed rare in those diagnosed at >60 years 
of age (2% cumulative incidence in SHaRe), all other 
risks, including AF, HF, and overall mortality, were great-
est in this age group.
When incident onset of events after diagnosis was 
examined, patients diagnosed at an older age appeared 
to have more rapid occurrence of events compared 
with those diagnosed young. These observations sug-
gest that although patients who are younger at diagno-
sis are more likely to experience at least 1 adverse event 
over the course of their lives, this burden is amortized 
over a long period of time. In contrast, patients who 
are older at diagnosis appear to have a lower cumula-
tive risk of adverse events over their lifetime. However, 
they are more likely than younger patients to have an 
incident event on an annualized basis after diagnosis, 
presumably caused at least partially by being older and 
having more comorbidities at the time of diagnosis. Ul-
timately, most patients with HCM are likely to experi-
ence adverse events.
The observed lag time from HCM diagnosis to most 
severe outcomes, particularly in those diagnosed as 
children or young adults, implies that adverse remodel-
ing progresses throughout life. Thus, there may be an 
extended window of opportunity to implement disease-
modifying therapies. There is a critical need to better 
understand the factors driving disease progression and 
Table 2. Multivariable Models Predicting Outcomes in the Genotyped Hypertrophic Cardiomyopathy Cohort
Overall 
Composite No. of Events, 1131 
No. of Patients, 2631
Ventricular Arrhythmia 
Composite No. of Events, 187 
No. of Patients, 2686
HF 
Composite No. of Events, 610 
No. of Patients, 2692
AF 
No. of Events, 596 
No. of Patients, 2589
HR
Lower 
95% CI
Upper 
95% CI P Value HR
Lower 
95% CI
Upper 
95% CI P Value HR
Lower 
95% CI
Upper 
95% CI P Value HR
Lower 
95% CI
Upper 
95% CI P Value
SARC+ 2.20 1.89 2.54 <0.001 2.83 2.07 3.87 <0.001 2.03 1.68 2.45 <0.001 2.41 1.98 2.94 <0.001
SARC VUS 1.57 1.22 2.02 <0.001 1.65 0.96 2.86 0.07 1.38 1.00 1.92 0.05 1.90 1.38 2.64 <0.001
Family 
proband
1.96 1.54 2.50 <0.001 6.65 2.72 16.26 <0.001 1.89 1.38 2.59 <0.001 1.87 1.36 2.57 <0.001
Female 0.88 0.77 1.01 0.07 0.69 0.51 0.94 <0.05 1.28 1.07 1.52 <0.01 0.72 0.60 0.87 <0.001
Nonwhite 1.01 0.80 1.90 0.91 1.50 0.96 2.34 0.08 0.99 0.73 1.34 0.94 0.92 0.66 1.28 0.63
AF indicates atrial fibrillation; HF, heart failure; HR, hazard ratio; SARC, sarcomere; and VUS, variants of uncertain significance.
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to develop effective treatment to delay or prevent the 
adverse remodeling that leads to HF and AF rather than 
treating these complications once they have already de-
veloped. To date, no such therapy is available for HCM. 
Translational approaches such as attenuation of fibro-
sis14–16 or allosteric myosin inhibitors17 may prove instru-
mental to hold disease in an early, relatively quiescent 
phase, thereby preventing adverse outcomes. Although 
these interventions may be predicted to have greatest 
impact in the preclinical phase of disease in young, at-
risk mutation carriers,14,18 the possibility of interrupting 
disease progression even after full phenotypic develop-
ment should also be actively pursued.
Genotype Influences Outcome
Prior small cohort studies suggested an excess hazard 
and earlier presentation associated with sarcomere mu-
tations.8,9,19–21 Data from this large multicenter cohort 
with rigorously curated genetic variants decisively sup-
port the conclusion that sarcomeric HCM is associated 
with worse outcomes than disease not caused by sarco-
mere mutations. Patients carrying sarcomere mutations 
with strong evidence for pathogenicity exhibited clinical 
disease at an earlier age and had a greater burden and 
earlier onset of HCM-related complications. The risk of 
developing the overall composite outcome by 50 years 
of age was 29% for SARC+ patients versus 14% for 
SARC− patients. Even after adjustment for earlier age 
at presentation, sarcomere mutations conferred signifi-
cant excess hazard. HCM management guidelines from 
the American College of Cardiology Foundation/Ameri-
can Heart Association and European Society of Cardi-
ology recommend genetic testing (Class IB) primarily 
to direct cascade assessments in family members. This 
study also underscores the value of genotype in guiding 
clinical management and determining the prognosis of 
patients with HCM. Indeed, our data suggest that mor-
tality in patients with nonfamilial HCM (no sarcomere 
mutation and no family history of HCM) may not be 
significantly higher than that of the US general popula-
tion. Although this finding requires confirmation and 
further characterization, it indicates that distinct dis-
ease subsets are currently grouped under the same 
broad designation of HCM, highlighting the need for 
more precise diagnostic strategies to improve risk strati-
fication and clinical management.
Sarcomere variants of unknown significance iden-
tified in patients with HCM are typically disregarded 
because of the ambiguity surrounding their clinical 
relevance. However, our data indicate that these vari-
ants can affect prognosis. SARC VUS patients were di-
agnosed earlier and had worse outcomes than SARC− 
patients. Indeed, SHaRe data positioned outcome risk 
associated with SARC VUS HCM as intermediate be-
tween SARC+ and SARC−. These findings imply that 
some VUSs are pathogenic variants, even if they cannot 
be interpreted as such by current clinical variant classi-
fication strategies that require stringent evidence to al-
low confident use in family cascade screening or predic-
tive genetic testing. Improved analytical pipelines and 
methods to determine variant pathogenicity are clearly 
needed to improve risk stratification and to enable pre-
dictive testing of family members.
Limitations
Inherent limitations to retrospective, registry-based ob-
servational studies are survivor bias and the fact that 
inferences about causality cannot be made. Analyses 
of other large cohorts such as the Hypertrophic Cardio-
myopathy Registry and the European HCM Registry22–24 
will provide important opportunities for collaborative 
study and confirmation of key findings.
Our estimates of cumulative morbidity are subject to 
the ascertainment limitations of the current SHaRe da-
tabase, including the retrospective data collection and 
lack of data on recurrent events. Given these limitations, 
cumulative morbidity from birth in the older age at di-
agnosis groups may be underestimated because these 
patients have a longer unobserved period when histori-
cal ascertainment of events may be less complete and a 
shorter period of follow-up after entry into SHaRe. Fur-
thermore, cumulative incidence estimates at older ages 
in the age at diagnosis <40 years stratum should be 
interpreted cautiously because of the small numbers of 
patients remaining at risk at these later ages. Because 
of the detailed collection of medical history at entry into 
SHaRe, we feel that historical events have been reliably 
captured and are as complete as possible. Recurrent 
events are not yet available in the SHaRe database, but 
efforts are underway to incorporate recurrent events in 
future studies to more completely account for the cu-
mulative burden of disease.
A limited subset of patients were potentially lost to 
follow-up, however the proportions were similar across 
a range of ages of diagnosis. Because baseline charac-
teristics in this subset were similar to the overall cohort, 
systematic bias resulting from patients lost to follow-up 
is unlikely (Table IV in the online-only Data Supplement). 
We also acknowledge that appropriate implantable car-
dioverter-defibrillator therapy is an imperfect surrogate 
for sudden cardiac death and likely overestimates risk 
because not all treated episodes may have been fatal.25 
This may particularly be the case for episodes treated 
only with antitachycardia pacing. Cox models for the 
ventricular arrhythmia composite did not differ signifi-
cantly after the exclusion of appropriate implantable 
cardioverter-defibrillator therapy events made up of only 
antitachycardia pacing (18 of 104 events; Table V in the 
online-only Data Supplement). Finally, SHaRe represents 
primarily an adult-onset cohort; only 422 patients (9%) 
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were <18 years old at the initial clinic visit. Efforts are 
underway to increase pediatric HCM representation and 
to compare pediatric with adult-onset disease.
CONCLUSIONS
The cumulative morbidity and mortality of HCM are 
substantial and disproportionately borne by patients di-
agnosed earlier in life and patients with sarcomere mu-
tations. Younger age at diagnosis and the presence of a 
sarcomere mutation were strong predictors of adverse 
events and should be incorporated into discussions 
about the prognosis for individual patients with HCM. 
Because the burden of HCM was dominated by HF and 
AF that developed later in life, continued surveillance in 
older patients, currently considered at low risk for HCM 
complications, is vital. Finally, a critical need and oppor-
tunity exist for developing disease-modifying therapies 
to interrupt progressive remodeling and adverse out-
comes in HCM.
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